Neoplastic Condition Affecting Patents (Class 514/19.2)
-
Patent number: 8822419Abstract: An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.Type: GrantFiled: October 2, 2009Date of Patent: September 2, 2014Assignee: The Research Foundation of State University of New YorkInventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
-
Patent number: 8822442Abstract: The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.Type: GrantFiled: October 28, 2005Date of Patent: September 2, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Michael Dewitt Culler, Yeelena Shen
-
Patent number: 8821883Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.Type: GrantFiled: October 4, 2012Date of Patent: September 2, 2014Assignee: Biogen Idec MA Inc.Inventors: Christine Ambrose, Jeffrey Thompson, Yen-Ming Hsu, Dingyi Wen, Yaping Sun
-
Patent number: 8815804Abstract: Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to tumors, sites of injury and blood clots in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tumors, sites of injury and blood clots.Type: GrantFiled: February 5, 2007Date of Patent: August 26, 2014Assignee: Sanford-Burnham Medical Research InstituteInventors: Erkki Ruoslahti, Jan Pilch
-
Publication number: 20140235550Abstract: Disclosed is a general methodology to create nanofibers of therapeutic molecules that have a dual role, as both the delivery vehicle and the drug itself. It is shown that with proper molecular design, the integration of enzymatic reaction and self-assembly provides a powerful method to create molecular hydrogels of clinically-used therapeutics without compromising their bioactivities. In addition, the results disclosed herein demonstrate enzyme-instructed self-assembly as a facile strategy for generating the supramolecular hydrogels of molecules that inherently have poor solubility in water. For example, by covalently connecting paclitaxel with a motif that is prone to self-assemble, a hydrogel of paclitaxel can be formed without compromising the activity of the paclitaxel.Type: ApplicationFiled: February 25, 2014Publication date: August 21, 2014Applicant: Brandeis UniversityInventors: Yuan Gao, Yi Kuang, Bing Xu
-
Patent number: 8808698Abstract: The present invention is directed to compositions and methods for inhibiting the development of new lymphatic vessels, and for inhibiting tumor cell dissemination through the lymphatics. In preferred embodiments, the present invention utilizes agents that inhibit the specific binding of integrin alpha4beta1 (?4?1, VLA-4) to one or more of its ligands. The invention further relates to methods for screening test compounds for their ability to inhibit undesirable lymphangiogenesis and/or tumor metastasis.Type: GrantFiled: February 5, 2007Date of Patent: August 19, 2014Assignee: The Regents of the University of CaliforniaInventors: Judith Varner, Barbara Garmy-Susini
-
Patent number: 8809280Abstract: The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted ? amino acid, each of the substituting groups in the ? amino acid, which may be the same or different, comprises at least (7) non-hydrogen atoms, is lipophilic and has at least one cyclic group, one or more cyclic groups within a substituting group may be linked or fused to one or more cyclic groups within the other substituting group and where cyclic groups are fused in this way the combined total number of non-hydrogen atoms for the two substituting groups is at least (12), for use as a cytolytic therapeutic agent; as well as non therapeutic uses of these molecules and certain defined novel compounds from within this definition.Type: GrantFiled: November 2, 2010Date of Patent: August 19, 2014Assignee: Lytix Biopharma ASInventors: Morten Strom, Terkel Hansen, Martina Havelkova, Veronika Torfoss
-
Publication number: 20140227221Abstract: Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents.Type: ApplicationFiled: December 4, 2013Publication date: August 14, 2014Applicant: Prolexys Pharmaceuticals, Inc.Inventors: Paul B. Robbins, Sudhir R. Sahasrabudhe
-
Publication number: 20140227260Abstract: The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: April 21, 2014Publication date: August 14, 2014Applicant: Auspex Pharmaceuticals, Inc.Inventor: Chengzhi Zhang
-
Patent number: 8802631Abstract: The invention is based on the discovery that STM/Hop promotes proliferation of human glioblastoma-derived cells but not of normal astrocytes and that the proliferation requires the binding of STM/Hop to PrPc. The invention is directed to methods for treating cancer which rely on interfering with the Hop-PrPc interaction and to peptides, and antibodies raised against the peptides, which directly provide that interference. The invention is further based on the discovery that STI1230-245 peptide and its human homologue Hop23o-245 provide the desired interference with the STI1/Hop-PrPc interaction and inhibit the STI 1/Hop-induced proliferation of glioma and glioblastoma cells. The invention is thus further directed to methods of treating cancer that employ these peptides and functional derivatives thereof, and antibodies directed to the peptides and derivatives. The invention is further directed to means of treating cancer which involve reducing the effective amount of Hop or reducing the expression of Hop.Type: GrantFiled: September 17, 2008Date of Patent: August 12, 2014Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Rafael Bierig Erlich, Luciana Chiarini, Vilma R. Martins, Rafael Linden, Vivaldo Moura Neto
-
Patent number: 8802634Abstract: The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-CD40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules.Type: GrantFiled: July 13, 2009Date of Patent: August 12, 2014Assignee: Phylogica LimitedInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Patent number: 8802635Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: GrantFiled: August 9, 2013Date of Patent: August 12, 2014Assignees: Oneday—Biotech And Pharma Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Publication number: 20140212438Abstract: Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.Type: ApplicationFiled: April 3, 2014Publication date: July 31, 2014Applicant: Yeda Research and Development Co., Ltd.Inventors: Rony SEGER, Dana Chuderland
-
Patent number: 8791285Abstract: An activatable nanoprobe is provided having a core component and an active agent associated with the core component via a bond configured to be cleaved upon exposure to an endogenous compound.Type: GrantFiled: June 11, 2012Date of Patent: July 29, 2014Assignee: University of Central Florida Research Foundation, Inc.Inventors: Swadeshmukul Santra, James Turkson
-
Publication number: 20140206635Abstract: A metal-salen complex compound, which exhibits excellent noninvasiveness and can be efficiently transferred to an affected site, a local anesthetic containing this metal-salen complex compound, and an antineoplastic drug containing this metal-salen complex compound are provided. Regarding the metal-salen complex compound, a metal atom part in each of two molecules of a metal-salen complex or a derivative of the metal-salen complex is dimerized via water, and the metal-salen complex compound is mixed with a base to produce an ointment.Type: ApplicationFiled: May 10, 2012Publication date: July 24, 2014Applicants: IHI CORPORATIONInventors: Yoshihiro Ishikawa, Haruki Eguchi
-
Patent number: 8785392Abstract: A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis.Type: GrantFiled: April 13, 2010Date of Patent: July 22, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, Kiwon Jo, Donghee Lee, Jung Yu, Ji Hyun Park, Chan-Woong Park, Eun Jin Kim, Yun Jung Park
-
Publication number: 20140193466Abstract: The present invention provides for silk-derived compositions for treating a wide variety of ocular conditions. The composition is produced by processing the silk cocoon into a water-based solution (i.e., a dissolved silk), which is then cast into a film. The film may be transparent to visible light, and curved in shape for easy application to the ocular surface. The silk film may either self-adhere or be sutured to cover the wound. The degradation time of the film may range from 1 minute to 24 hours, or from 2 hours to 20 hours. The present compositions can help regenerate damaged corneal tissue, thus promoting healing.Type: ApplicationFiled: June 7, 2012Publication date: July 10, 2014Applicant: CORNELL UNIVERSITYInventors: Brian D Lawrence, Alejandro Navas, Mark I. Rosenblatt
-
Patent number: 8771691Abstract: The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.Type: GrantFiled: December 14, 2009Date of Patent: July 8, 2014Assignee: Inserm (Institut National de la Sante et de la Recherche Medicale)Inventors: Patricia Forgez, Marco Alifano
-
Publication number: 20140186335Abstract: The present invention provides certain tetrahydrouridine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of making and using such compounds.Type: ApplicationFiled: November 25, 2013Publication date: July 3, 2014Applicant: Eisai Inc.Inventors: Gregory S. Hamilton, Takashi Tsukamoto, Dana V. Ferraris, Bridget Duvall, Rena Lapidus
-
Publication number: 20140187494Abstract: The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-?B or a STAT, and block inflammatory response mediated by NF-?B or STAT signaling.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicants: GENUS ONCOLOGY, LLC, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Donald W. KUFE, Surender KHARBANDA
-
Patent number: 8765687Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.Type: GrantFiled: October 17, 2006Date of Patent: July 1, 2014Assignee: Sloan Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Javier Pinilla-Ibarz, Rena May
-
Patent number: 8765683Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.Type: GrantFiled: January 29, 2012Date of Patent: July 1, 2014Assignee: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
-
Patent number: 8765909Abstract: The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotropic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids, the metastin derivatives of the present invention achieve more improved blood stability, solubility, etc., reduced gelation tendency, improved pharmacokinetics, as well as exhibit an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity. The metastin derivatives of the present invention also have a gonadotropic hormone secretion suppressing activity, sex hormone secretion suppressing activity, etc.Type: GrantFiled: October 24, 2007Date of Patent: July 1, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Taiji Asami, Naoki Nishizawa
-
Patent number: 8753638Abstract: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.Type: GrantFiled: February 13, 2013Date of Patent: June 17, 2014Assignee: aTyr Pharma, Inc.Inventors: Jie Zhou, Ching-Fun Lau, Zhiwen Xu, Wing-Sze Lo, Kristi Helen Piehl, Leslie Ann Greene
-
Patent number: 8754034Abstract: The invention provides methods for designing peptides that inhibit aggregation in target polypeptides. The candidate inhibitory peptidic compounds have an oligomeric sequence that forms energetically-favorable interactions with the amino acid sequence of the steric zipper region of the target protein, and also possess a zipper-disrupting feature that disrupt the peptide stacking at the steric zipper region. This method can be used to obtain inhibitory peptides to disrupt fibril formation involving any protein for which a steric zipper sequence can be identified. The invention also provides inhibitory peptidic compounds, which can be used in pharmaceutical compositions and methods for treating polypeptide aggregation-associated diseases or conditions.Type: GrantFiled: February 8, 2010Date of Patent: June 17, 2014Assignees: The Regents of the University of California, University of WashingtonInventors: David S. Eisenberg, Stuart A. Sievers, John Karanicolas, David Baker
-
Patent number: 8748175Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.Type: GrantFiled: November 2, 2009Date of Patent: June 10, 2014Assignee: Green Cross CorporationInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo, Jong-Hwa Won, Min-Kyu Hur
-
Patent number: 8748470Abstract: The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.Type: GrantFiled: March 16, 2012Date of Patent: June 10, 2014Assignee: The University of ChicagoInventors: Ernst Lengyel, Kristin Nieman, Hilary Kenny
-
Patent number: 8748388Abstract: Antitumoral compounds of Formula I, and pharmaceutically acceptable salts, derivatives, tautomers, prodrugs or stereoisomers thereof useful as antitumour agents.Type: GrantFiled: December 10, 2008Date of Patent: June 10, 2014Assignee: Pharma Mar, S.A.Inventors: Judit Tulla-Puche, Eleonora Marcucci, NĂşria BayĂł-Puxan, Fernando Albericio, Maria del Carmen Cuevas Marchante
-
Patent number: 8741849Abstract: The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population.Type: GrantFiled: August 7, 2008Date of Patent: June 3, 2014Assignee: Purdue Research FoundationInventors: Alyssa Panitch, Brandon Seal, Brian Ward
-
Patent number: 8741306Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.Type: GrantFiled: June 5, 2009Date of Patent: June 3, 2014Assignee: The Regents of the University of CaliforniaInventors: Arie Belldegrun, Cho-Lea Tso
-
Patent number: 8734775Abstract: Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the ?-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.Type: GrantFiled: August 26, 2011Date of Patent: May 27, 2014Assignees: University of Pittsburgh, Tuskegee UniversityInventors: Cecelia C. Yates-Binder, Jesse Jaynes, Timothy Turner, Alan Wells, Richard J. Bodnar
-
Publication number: 20140142044Abstract: Novel compounds are provided that bind to polo-like kinases through the polo-box domain. In certain embodiments, the novel compounds are PEGylated peptides. The PEGylated peptides in accordance with the invention demonstrate high PBD-binding affinity. In certain embodiments, the PEGylated peptides have also achieved activities in whole cell systems. The invention also provides compounds that bind polo-like kinases through the polo-box domain and possess reduced anionic charge. Further provided are methods of design and/or synthesis of the PEGylated peptides and methods of use thereof. The invention provides methods of use of the compounds and methods of synthesis of the compounds. The compounds of the invention have potential therapeutic activity in view of their binding and inhibitory activities towards Plk1. They are based on the amino acid sequence PLHSpT (phosphorylated Thr). The PEG moiety, when present, is covalently attached at the N-terminus.Type: ApplicationFiled: April 12, 2012Publication date: May 22, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health & Human ServicInventors: Terrence R. Burke, JR., Wenjian Qian, Fa Liu, Kyung S. Lee, Jung-Eun Park
-
Patent number: 8728483Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: GrantFiled: June 26, 2012Date of Patent: May 20, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
-
Publication number: 20140135271Abstract: In one embodiment, the present invention provides methods of modulating the deacetylase activity of SIRT1 in one or more cell by modifying the binding affinity of lamin A to SIRT1 via one or more interaction modifying compound. In another embodiment, the present invention provides methods of screening SIRT1-activating/inhibiting compounds based on the interaction between lamin A and SIRT1 proteins and SIRT1-activating property of lamin A. In another embodiment, the present invention provides uses of SIRT1-activating compounds to treat patient(s) suffering from metabolic and/or aging-related degenerative diseases, and uses of SIRT1-inhibiting compounds to treat human malignancies.Type: ApplicationFiled: November 12, 2013Publication date: May 15, 2014Applicant: THE UNIVERSITY OF HONG KONGInventors: Zhongjun Zhou, Baohua Liu
-
Patent number: 8722629Abstract: The present application relates to novel derivatives of monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and also to the use of these derivatives for preparing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as, for example, cancerous disorders. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: June 6, 2011Date of Patent: May 13, 2014Assignee: Seattle Genetics, Inc.Inventors: Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Sven Golfier, Joachim Schuhmacher, Ursula Krenz
-
Patent number: 8716243Abstract: Compositions and methods related to Wnt signaling regulation by Dickkopf (Dkk) polypeptides and Wnt-related diseases are disclosed. For example, compounds that bind a Dkk or LRP polypeptide are disclosed. Compounds that disrupt binding of a Dkk polypeptide to an LRP polypeptide are also disclosed. Methods for using the described compounds and compositions are also disclosed.Type: GrantFiled: May 22, 2009Date of Patent: May 6, 2014Assignee: St. Jude Childen's Research HospitalInventor: Jie Zheng
-
Patent number: 8715619Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.Type: GrantFiled: February 11, 2013Date of Patent: May 6, 2014Assignee: Cellerant Therapeutics, Inc.Inventor: Holger Karsunky
-
Patent number: 8716233Abstract: The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients.Type: GrantFiled: May 22, 2009Date of Patent: May 6, 2014Assignees: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Jon C. Aster, Stephen C. Blacklow, A. Thomas Look, Adolfo A. Ferrando, Andrew P. Weng
-
Publication number: 20140121170Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: ApplicationFiled: August 30, 2013Publication date: May 1, 2014Inventors: Vincent Craig BOND, Michael POWELL, MingBo HUANG, Syed ALI, Andrea D. RAYMOND, Martin Neville SHELTON, Francois Jean VILLINGER
-
Patent number: 8709998Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.Type: GrantFiled: April 21, 2004Date of Patent: April 29, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Yeelena Shen, Jeanne Mary Comstock, Sun H. Kim
-
Patent number: 8709995Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: August 20, 2007Date of Patent: April 29, 2014Assignees: Geron Corporation, The Regents of the University of ColoradoInventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 8703143Abstract: According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members.Type: GrantFiled: August 21, 2007Date of Patent: April 22, 2014Assignee: Philogen S.p.A.Inventors: Dario Neri, Barbara Carnemolla, Luciano Zardi, Gregory Paul Winter
-
Patent number: 8691764Abstract: The present invention provides a method for inhibiting NF-?B activity in a subject, the method comprising providing an agent capable of inducing expression of annexin 1, whereby said agent induces expression of annexin 1 and whereby said induced expression of annexin 1 inhibits NF-?B activity. Also provided are annexin 1 mimetics capable of binding to NF-?B and pharmaceutical compositions of such inducing and mimetic agents.Type: GrantFiled: March 28, 2008Date of Patent: April 8, 2014Assignee: The Research Foundation for the State University of New YorkInventors: Zhiquan Zhang, Basil Rigas
-
Patent number: 8685929Abstract: This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biological sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biological sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal.Type: GrantFiled: April 10, 2012Date of Patent: April 1, 2014Assignee: The Regents of the University of CaliforniaInventors: Donna G. Albertson, Daniel Pinkel, Colin Collins, Joe W. Gray, Bauke Ylstra
-
Patent number: 8685403Abstract: Interaction between insulin-like growth factor 1 (IGFI) and integrin is involved in integrin-mediated cellular signaling, such as enhanced proliferation of cells expressing integrins, especially integrin alpha v beta 3, alpha 6 beta. 1 and alpha 6. beta. 4. A method for inhibiting integrin signaling by using an inhibitor of IGFI-integrin binding is disclosed A method for identifying inhibitors of IGFI-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, and corresponding compositions for inhibiting integrin signaling.Type: GrantFiled: January 29, 2010Date of Patent: April 1, 2014Assignee: The Regents of the University of CaliforniaInventors: Yoshikazu Takada, Jun Saegusa
-
Publication number: 20140088016Abstract: The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.Type: ApplicationFiled: May 17, 2012Publication date: March 27, 2014Applicant: University of Florida Research Foundation, Inc.Inventor: Hendrik Luesch
-
Patent number: 8680041Abstract: Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided.Type: GrantFiled: October 24, 2007Date of Patent: March 25, 2014Assignee: Genentech, Inc.Inventors: Zhengyan Kan, Denise M. Kenski, Brock Peters, Somasekar Seshagiri
-
Patent number: 8679471Abstract: The present invention relates to compositions and methods for modulating the presence and/or activity of regulatory T cells in a subject.Type: GrantFiled: September 30, 2011Date of Patent: March 25, 2014Assignee: The Trustees of the Univesity of PennsylvaniaInventors: Richard G. Carroll, Xiaochuan Shan, Gwenn-ael Danet-Desnoyers, Carl H. June
-
Patent number: 8680056Abstract: A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.Type: GrantFiled: May 3, 2007Date of Patent: March 25, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, Baltimore, The United States of America as Represented by the Department of Veterans AffairsInventors: Susan K. Keay, Zoltan Szekely, Thomas Conrads, Timothy Veenstra, Maria Michejda
-
Patent number: 8674070Abstract: Cancer-targeting peptides and uses thereof in cancer therapy.Type: GrantFiled: February 19, 2010Date of Patent: March 18, 2014Assignee: Academia SinicaInventors: Han-Chung Wu, Chien-Yu Chiu